OCT-Angiography and Adaptive Optics in Patients With Memory Impairment

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04389437

Acronym

OCTAVO

Enrollment

450

Registered

2020-05-15

Start date

2020-06-26

Completion date

2026-06-30

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Amnesia, Lewy Body Disease, Parkinsons Disease With Dementia

Keywords

OCT-A, adaptative optics

Brief summary

Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or Lewy body diseases. These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD. No study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.

Interventions

PROCEDUREOphthalmological exam

OCT-A and AO

PROCEDUREBlood pressure measurement

Blood pressure measurement before the ophthalmological exam

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint

Exclusion criteria

* pregnant or lactating women * history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis) * history of retinal pathology * ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder. * history of taking ethambutol for more than 2 months * history of takingsynthetic antimalarial for more than 2 years * Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) \<10 for patients and 26 for accompanying persons * MRI contraindication (for patients only)

Design outcomes

Primary

Measure	Time frame	Description
Wall to lumen ratio (WLR)	Baseline (Inclusion)	Measured in adaptive optics, compared between patients case with NCD and patient controls without NDC found

Countries

France

Contacts

Primary ContactAmélie YACHITZ, MD

ayavchitz@for.paris(0)148036454

Backup ContactAntoine MOULIGNIER, MD

amoulignier@for.paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026